TSRX Insider Trading Activity and SEC Form 4 Filings
TSRX insider trading summary
No open-market insider purchases or sales of Trius Therapeutics Inc (TSRX) have been reported on SEC Form 4 in the past 12 months.
Latest TSRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 22, 2013 | John Finn | Chief Scientific Officer | Sell | $12K (1,000 @ $12.10) |
| Jul 15, 2013 | John Finn | Chief Scientific Officer | Sell | $37K (3,500 @ $10.55) |
| Jul 12, 2013 | John Finn | Chief Scientific Officer | Sell | $51K (5,000 @ $10.10) |
| Jul 11, 2013 | Michael Morneau | VP Finance & CAO | Sell | $195K (20,000 @ $9.75) |
| Jul 11, 2013 | John Finn | Chief Scientific Officer | Sell | $5K (500 @ $9.32) |
| Jul 10, 2013 | John Finn | Chief Scientific Officer | Sell | $9K (1,000 @ $8.58) |
| Jul 1, 2013 | Ken Bartizal | Chief Development Officer | Sell | $16K (2,000 @ $8.14) |
| Jul 1, 2013 | Philippe Prokocimer | Chief Medical Officer | Sell | $16K (2,000 @ $8.14) |
| Jun 12, 2013 | John Finn | Chief Scientific Officer | Sell | $27K (3,000 @ $9.08) |
| Jun 11, 2013 | John Finn | Chief Scientific Officer | Sell | $9K (1,000 @ $8.94) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.